Alembic Pharma gets USFDA’s final approval for Bosentan Tablets

24 Jan 2020 Evaluate

Alembic Pharmaceuticals (Alembic) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bosentan Tablets, 62.5 mg and 125 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Tracleer Tablets, 62.5 mg and 125 mg, of Actelion Pharmaceuticals.

Bosentan Tablets indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1). Bosentan Tablets, 62.5 mg and 125 mg have an estimated market size of $68 million for twelve months ending September 2019 according to IQVIA.

Alembic has a cumulative total of 114 ANDA approvals (102 final approvals and 12 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

838.70 -13.60 (-1.60%)
29-Dec-2025 14:36 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.20
Dr. Reddys Lab 1267.55
Cipla 1494.85
Zydus Lifesciences 906.00
Lupin 2086.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×